ANO1和E-钙黏蛋白在人原发性结直肠癌组织中的表达及其意义

doi:10.13481/j.1671-587X.20250619

Abstract

Abstract:

Objective To explore the expressions of calcium-activated chloride channel protein 1（ANO1） and E-cadherin in colorectal cancer （CRC） tissue and their relationships with the clinicopathological characteristics of the CRC patients， and to clarify their clinical significances. Methods The surgical tissue specimens from 77 patients with primary CRC were collected. Immunohistochemistry （IHC） method was used to detect the protein expressions of ANO1 and E-cadherin in CRC tissue； Spearman correlation analysis method was used to analyze the correlation between their expressions； PCR fluorescence probe method was used to detect the KRAS/NRAS mutations in CRC tissue； chi-square test or Fisher’s exact probability method was used to analyze the relationships between the expressions of ANO1 and E-cadherin and clinicopathological characteristics of the CRC patients. Results The IHC results showed that the positive expression rate of ANO1 in CRC tissue was 24.7%， and the positive expression rate of E-cadherin was 63.6%. The Spearman analysis results showed that the expressions of ANO1 and E-cadherin in CRC tissue were positively correlated （r=0.458， P<0.05）. Compared with the patients with tumor located in rectum， the positive expression rate of ANO1 in cancer tissue of the CRC patients with tumor located in colon was significantly increased （χ²=5.499， P=0.019）； compared with the patients with TNM stage Ⅲ-Ⅳ， the positive expression rate of ANO1 in cancer tissue of the CRC patients with TNM stage Ⅰ-Ⅱ was significantly increased （χ²=4.774， P=0.029）； compared with the patients with lymphnode metastasis， the positive expression rate of ANO1 in the CRC patients without lymphnode metastasis was significantly increased （P=0.034）. Compared with the CRC patients with T4 stage， the positive expression rate of E-cadherin in the CRC patients with T1-T3 stage was significantly increased （P=0.024）. Compared with the CRC patients with p53 positive， Ki-67≥90%， PMS2 positive and KRAS wild-type， the positive expression rate of ANO1 in cancer tissue of the CRC patients with p53 negative， Ki-67<90%， PMS2 negative and KRAS mutant was significantly increased （P=0.031， P=0.036， P=0.048， P=0.028）. Conclusion The expressions of ANO1 and E-cadherin in primary CRC tissue of the patients are positively correlated； ANO1 and E-cadherin are associated with multiple clinicopathological characteristics of the patients； ANO1 and E-cadherin may be involved in the occurrence and progression of CRC.

Key words: Colorectal cancer, Anoctamin 1, E-cadherin, Immunohistochemistry, Clinicopathological characteristics

CLC Number:

R735.3

Fei WU,Qiwei YANG,Xin LI,Linxian ZHAO,Yujie SUI. Expressions of ANO1 and E-cadherin in human primary colorectal cancer tissue and their significances[J].Journal of Jilin University(Medicine Edition), 2025, 51(6): 1638-1645.

Figures/Tables 5

Fig. 1

Fig.2

Tab.1

Tab.2

Tab.3

References 24

[1]	ZHENG R S， CHEN R， HAN B F， et al. Cancer incidence and mortality in China， 2022［J］. Zhonghua Zhong Liu Za Zhi， 2024， 46（3）： 221-231.
[2]	SHIN A E， GIANCOTTI F G， RUSTGI A K. Metastatic colorectal cancer： mechanisms and emerging therapeutics［J］. Trends Pharmacol Sci， 2023， 44（4）： 222-236.
[3]	JIANG F L， JIA K R， CHEN Y， et al. ANO1-mediated inhibition of cancer ferroptosis confers immunotherapeutic resistance through recruiting cancer-associated fibroblasts［J］. Adv Sci， 2023， 10（24）： 2300881.
[4]	AL-HOSNI R， ILKAN Z， AGOSTINELLI E， et al. The pharmacology of the TMEM16A channel： therapeutic opportunities［J］. Trends Pharmacol Sci， 2022， 43（9）： 712-725.
[5]	TAMMARO P. The TMEM16A anion channel as a versatile regulator of vascular tone［J］. Sci Signal， 2023， 16（811）： eadk5661.
[6]	OKUYAMA K， YANAMOTO S. TMEM16A as a potential treatment target for head and neck cancer［J］. J Exp Clin Cancer Res， 2022， 41（1）： 196.
[7]	LI S T， WANG Z C， GENG R L， et al. TMEM16A ion channel： a novel target for cancer treatment［J］. Life Sci， 2023， 331： 122034.
[8]	DENG C M， ZHANG G G， LIU Q W， et al. ANO1 reprograms cholesterol metabolism and the tumor microenvironment to promote cancer metastasis［J］. Cancer Res， 2023， 83（11）： 1851-1865.
[9]	CORSO G， FIGUEIREDO J， DE ANGELIS S P， et al. E-cadherin deregulation in breast cancer［J］. J Cell Mol Med， 2020， 24（11）： 5930-5936.
[10]	KIELBIK M， SZULC-KIELBIK I， KLINK M. E-cadherin expression in relation to clinicopathological parameters and survival of patients with epithelial ovarian cancer［J］. Int J Mol Sci， 2022， 23（22）： 14383.
[11]	龙明，张松峰. 外科学［M］. 8版. 北京：人民卫生出版社， 2018： 387-394.
[12]	郭超杰，张佳佳，曾洁，等. PLOD1在口腔鳞状细胞癌组织和细胞中的表达及其意义［J］. 吉林大学学报（医学版）， 2024， 50（4）： 1035-1043.
[13]	SIEGEL R L， MILLER K D， JEMAL A. Cancer statistics， 2020［J］. CA A Cancer J Clin， 2020， 70（1）： 7-30.
[14]	ZHANG G N， SHU Z H， YU J， et al. High ANO1 expression is a prognostic factor and correlated with an immunosuppressive tumor microenvironment in pancreatic cancer［J］. Front Immunol， 2024， 15： 1341209.
[15]	CHEN W J， GU M， GAO C B， et al. The prognostic value and mechanisms of TMEM16A in human cancer［J］. Front Mol Biosci， 2021， 8： 542156.
[16]	刘军，汪玲，姜钰环，等. 免疫原性细胞死亡基因风险模型的建立及其对肝细胞癌预后和肿瘤微环境特征的预测价值［J］. 临床肝胆病杂志， 2024， 40（12）： 2473-2483.
[17]	JANSEN K， FARAHI N， BÜSCHECK F， et al. DOG1 expression is common in human tumors： a tissue microarray study on more than 15， 000 tissue samples［J］. Pathol Res Pract， 2021， 228： 153663.
[18]	中国临床肿瘤学会（CSCO）结直肠癌专家委员会. 结直肠癌分子标志物临床检测中国专家共识［J］. 中华胃肠外科杂志， 2021， 24（3）： 191-197.
[19]	YUAN C F， HUANG J N， WANG Y Z， et al. Exploration and validation of the Ki67， Her-2， and mutant P53 protein-based risk model， nomogram and lymph node metastasis model for predicting colorectal cancer progression and prognosis［J］. Front Oncol， 2023， 13： 1236441.
[20]	ZHU G M， PEI L J， XIA H W， et al. Role of oncogenic KRAS in the prognosis， diagnosis and treatment of colorectal cancer［J］. Mol Cancer， 2021， 20（1）： 143.
[21]	陈劲松，王丹. 肿瘤新抗原在肿瘤免疫治疗中的应用研究进展［J］. 解放军医学杂志， 2024， 49（10）： 1213-1220.
[22]	WONG S H M， FANG C M， CHUAH L H， et al. E-cadherin： Its dysregulation in carcinogenesis and clinical implications［J］. Crit Rev Oncol Hematol， 2018， 121： 11-22.
[23]	CHANG K B， JIANG L， SUN Y F， et al. Effect of E-cadherin on prognosis of colorectal cancer： a meta-analysis update［J］. Mol Diagn Ther， 2022， 26（4）： 397-409.
[24]	左汪洋，孙佳春，王蓓蕾，等. 环氧化酶-2、β-连环蛋白和E-钙黏蛋白在结直肠癌中的表达及临床意义［J］. 中国肛肠病杂志， 2022， 42（12）： 1-5.

Clinicopathological characteristic	Total case	ANO1 positive			E-cadherin positive
Clinicopathological characteristic	Total case	Number [n（η/%）]	χ²	P	Number [n（η/%）]	χ²	P
Age (year)
<60	32	6（18.8）	1.034	0.309^a	20（62.5）	0.031	0.861^a
≥60	45	13（28.9）	1.034	0.309^a	29（64.4）	0.031	0.861^a
Gender
Male	52	13（25.0）	0.009	0.924^a	35（67.3）	0.933	0.334^a
Female	25	6（24.0）	0.009	0.924^a	14（56.0）	0.933	0.334^a
Tumor location
Colon	31	12（38.7）	5.499	0.019^a	21（67.7）	0.378	0.539^a
Rectum	46	7（15.2）	5.499	0.019^a	28（60.9）	0.378	0.539^a
Histological type
Adenocarcinoma	66	18（27.3）	-	0.275^b	42（63.6）	<0.01	>0.999^a
Non-Adenocarcinoma	11	1（9.0）	-	0.275^b	7（63.6）	<0.01	>0.999^a
Differentiation
Well+Medium	60	15（25.0）	-	>0.999^b	38（63.3）	0.010	0.917^a
Poor	17	4（23.5）	-	>0.999^b	11（64.7）	0.010	0.917^a
TNM stage
Ⅰ+Ⅱ	40	14（35.0）	4.774	0.029^a	27（67.5）	0.537	0.464^a
Ⅲ+Ⅳ	37	5（13.5）	4.774	0.029^a	22（59.4）	0.537	0.464^a
T stage
T1-T3	69	18（26.1）	-	0.671^b	47（68.1）	-	0.024^b
T4	8	1（12.5）	-	0.671^b	2（25.0）	-	0.024^b
Lymphnode
N0	40	14（35.0）	-	0.034^b	27（67.5）	1.324	0.516^a
N1	19	3（15.7）			10（52.6）
N2	18	2（11.1）			12（66.7）

IHC feature	Total case	ANO1 positive			E-cadherin positive
IHC feature	Total case	Number [n（η/%）]	χ²	P	Number [n（η/%）]	χ²	P
p53
Positive	52	9（17.3）	4.677	0.031^a	30（57.7）	2.445	0.118^a
Negative	25	10（40.0）	4.677	0.031^a	19（76.0）	2.445	0.118^a
EGFR
Positive	55	12（21.8）	0.968	0.325^a	37（67.3）	1.736	0.188^a
Negative	18	6（33.3）	0.968	0.325^a	9（50.0）	1.736	0.188^a
Ki67
≥90%	32	4（12.5）	-	0.036^b	18（56.3）	1.632	0.201^a
<90%	44	15（34.1）	-	0.036^b	31（70.5）	1.632	0.201^a
CD34
Positive	22	4（18.2）	-	0.123^b	12（54.5）	2.975	0.085^a
Negative	27	11（40.7）	-	0.123^b	21（77.8）	2.975	0.085^a
CDX2
Positive	73	19（26.0）	-	0.569^b	46（63.0）	1.721	0.190^b
Partially positive	3	0（0.0）	-	0.569^b	3（100.0）	1.721	0.190^b
PMS2
Positive	71	16（24.2）	-	0.048^b	45（63.4）	-	>0.999^b
Negative	4	3（75.0）	-	0.048^b	3（75.0）	-	>0.999^b
MLH1
Positive	66	16（26.7）	-	0.684^b	42（63.6）	0.031	0.859^b
Negative	9	3（33.3）	-	0.684^b	6（66.7）	0.031	0.859^b
MSH2
Positive	73	17（23.3）	-	0.061^b	46（63.0）	-	0.533^b
Partially positive	2	2（100.0）	-	0.061^b	2（100.0）	-	0.533^b
MSH6
Positive	66	16(24.2)	-	0.684^b	42（63.6）	-	>0.999^b
Negative	9	3（33.3）	-	0.684^b	6（66.7）	-	>0.999^b

Gene mutation	Item	n	ANO1 positive			E-cadherin positive
Gene mutation	Item	n	Number [n（η/%）]	χ²	P	Number [n（η/%）]	χ²	P
KRAS (codon 12/13)	Mutant type	32	12（37.5）	4.845	0.028^a	20（62.5）	0.031	0.861^a
KRAS (codon 12/13)	Wild type	45	7（15.6）	4.845	0.028^a	29（64.4）	0.031	0.861^a
NRAS(codon12/13 /59/61/117/46)	Mutant type	3	1（33.3）	-	>0.999^b	3（100.0）	-	0.297^b
NRAS(codon12/13 /59/61/117/46)	Wild type	74	18（24.3）	-	>0.999^b	46（62.2）	-	0.297^b

Expressions of ANO1 and E-cadherin in human primary colorectal cancer tissue and their significances

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 5

References 24

Related Articles 15

Metrics

Comments

Recommended 10

[1]	Yu LIANG,Jinyu YU,Zhonggao XU,Wanning WANG. Expression characteristics of FOSB in kidney tissue from IgA nephropathy and other common kidney diseases [J]. Journal of Jilin University(Medicine Edition), 2025, 51(5): 1281-1292.
[2]	Changyu SHI,Yong LI,Jing DENG,Chunmei PIAO,Ming JIN. Bioinformatics analysis on adjustment effect of colorectal liver metastases model in mice based on complement alternative pathway and its experimental verification [J]. Journal of Jilin University(Medicine Edition), 2025, 51(3): 703-715.
[3]	Huaxia MU,Weixiao BU,Shuting DING,Mengyao GAO,Weiqiang SU,Zhen ZHANG,Qifu BO,Feng LIU,Fuyan SHI,Qinghua WANG,Yujia KONG,Suzhen WANG. Two sample Mendelian randomization study on causal relationship between insulin-like growth factor-1 and colorectal cancer [J]. Journal of Jilin University(Medicine Edition), 2025, 51(2): 479-485.
[4]	Haiying GENG,Yan YU,Chunmei DAI,Youfeng WEN,Ning LI. Expression of TRIM24 protein in human clear cell renal cell carcinoma tissue and its clinical significance [J]. Journal of Jilin University(Medicine Edition), 2025, 51(2): 486-492.
[5]	Xiaoming WANG,Xueye WANG. Invasive adenocarcinoma of lung complicated with metastatic NUT midline carcinoma of mediastinal lymph node： A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2024, 50(3): 825-830.
[6]	Rongxia JIA,Xu ZHOU,Zhikun SHI,Meijing BAO,Guanqun WANG,Yuqing CHU,Yang JIN,Yang LIN. Recurrent vulvar angiomyofibroblastoma :A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2023, 49(1): 193-197.
[7]	Yunhe GAO,Jianan YAO,Lanqing CAO,Chuanjie XU. Clinicopathological characteristics and analysis on prognostic factors of patients with solitary fibrous tumors in different sites [J]. Journal of Jilin University(Medicine Edition), 2022, 48(6): 1510-1517.
[8]	Aiping WEN,Le LUO,Zhiwei MENG,Jingji JIN,Honggui ZHOU,Jihong ZHU. Expression of Tip60 protein in endometrial adenocarcinoma tissue and its clinical significance [J]. Journal of Jilin University(Medicine Edition), 2021, 47(5): 1244-1249.
[9]	Meisi REN,Yu FAN,Qingrui XUE,Tianyu WANG,Guangxiang ZANG,Hongchen SUN. Alveolar soft part sarcoma of right buccal mucosa: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2021, 47(5): 1281-1286.
[10]	Qi ZHU,Lamei LI,Yanjun CAI,Fang XU,Junqi NIU,Wanyu LI. Hepatoid adenocarcinoma of stomach:A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2021, 47(4): 1028-1032.
[11]	BAN Shuofeng, ZHANG Shichen, SUN Yidan, WANG Jing, HAN Bing. Expressions of heterogeneous nuclear ribonucleoprotein D and epithelial cell adhesion molecule in oral squamous cell carcinoma tissue and their significances [J]. Journal of Jilin University(Medicine Edition), 2020, 46(03): 589-593.
[12]	DENG Ying, ZHU Yuzhen, WU Kefeng, ZHENG Xuebao, YE Hua. Effect of lncRNA H19 up-regulation mediated by IL-6/ STAT3 pathway in pathogenesis of ulcerative colitis-associated colorectal cancer in mice [J]. Journal of Jilin University(Medicine Edition), 2020, 46(01): 20-25.
[13]	LIU Xiuhua, WANG Man, DONG Xinjie, LIU Jingnan, HAN Wei, GUAN Yinghui. Expression of filamin A in cancer tissue of cervical cancer patients and its clinical significance [J]. Journal of Jilin University(Medicine Edition), 2019, 45(06): 1238-1242.
[14]	WANG Chuang, YU Shuli, LI Tao, LYU Rongrong, QI Jiemin. Expressions of heparanase and integrin α5β1 proteins in hydatidform mole tissue and their clinnical significances [J]. Journal of Jilin University(Medicine Edition), 2019, 45(06): 1361-1366.
[15]	LI Hua, CAO Yansha, ZHAO Jinping, REN Fu, LI Ning. Expression of SIRT6 protein in colon cancer tissue detected by tissue microarray technique and its clinical significance [J]. Journal of Jilin University(Medicine Edition), 2019, 45(04): 893-898.